LightWave I Clinical Trial Confirms Safety and Short-term Efficacy of Light Modulation® LLLT (PBM) on eye-light® for dAMD

 

Espansione Group is thrilled to announce the release of the 6-Month milestone publication of the DRUSEN Study, part of the greater LightWave I research effort — a multicentric clinical trial aimed at studying the impact of LM® LLLT on dAMD Patients. 

The study has been published in the September Issue of Springer’s Ophthalmology & Therapy Journal. In the study, part of a longer longitudinal, double-masked multicentric trial effort, the safety, tolerability, and short-term efficacy of Light Modulation® Low-Level Light Therapy (LM® LLLT) for patients with Dry Age-Related Macular Degeneration (dAMD) has been proven.

Whilst a total of over 200 patients were enrolled within LightWave I, 152 eyes from 76 patients were admitted into the sample.

Given the significant impact on quality of life and the related social costs of AMD, diagnosing, monitoring, and treating the disease are poised to become major challenges for the global ophthalmology community in the coming years. Research efforts and innovative therapeutic approaches such as LM® LLLT (PBM) are focusing on slowing the progression of the disease and preventing the advanced stages, characterized by either outer retinal and RPE atrophy, or development of wet AMD.

Prof. Enrico Borrelli (MD, PhD), lead investigator of the study from University of Turin, noted that, “The LightWave I trial and the DRUSEN study represent a major milestone deepening our understanding of light therapy’s impact in the management of degenerative retinal conditions such as dry AMD.”

Reporting directly from the recent publication:

• Changes in best‐corrected visual acuity (BCVA) from baseline to month 4 differed significantly between the sham and PBM‐treated groups, favoring the latter, with a higher pro‐ portion achieving a gain of five or more letters post‐treatment (8.9% vs. 20.3%, respectively; p=0.043).
• The study also found a statistically significant dispar‐ ity in mean drusen volume changes from baseline to month 4 between the groups in favor of patients treated with PBM (p=0.013).

Access the full-length publication via the Bibliography section on our website.

 

> ABOUT ESPANSIONE GROUP

Espansione Group is an established player in the medtech industry. Since 1981, Espansione Group has delivered the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL).

Present in over 50 countries, Espansione Group aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence.  

 

For more information, see www.espansionegroup.it

Media Contacts

Espansione Group Press Office
press@espansione.it 
© 2024 Espansione Group, All Rights Reserved
Posted on September 21st, 2024 in Newsroom